In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile

Background: Clostridium difficile (C. difficile) is a major nosocomial pathogen that colonizes in the human gut. Recently, the U.S. FDA approved three new antimicrobial agents against gram-positive bacteria: Tedizolid, Dalbavancin, and Ceftobiprole. The efficacy of these antibiotics for treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Binyamin, Dana, Nitzan, Orna, Azrad, Maya, Hamo, Zohar, Koren, Omry, Peretz, Avi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004428/
https://www.ncbi.nlm.nih.gov/pubmed/29942295
http://dx.doi.org/10.3389/fmicb.2018.01256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004428/
https://www.ncbi.nlm.nih.gov/pubmed/29942295
http://dx.doi.org/10.3389/fmicb.2018.01256

Ejemplares similares